Inflammation, infection and atherosclerosis: Do antibacterials have a role in the therapy of coronary artery disease?

Drugs

Volumn 59, Issue 2, 2000, Pages 159-170

  Mehta, Jawahar L ^a,c   Romeo, Francesco ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CYTOKINE; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; MACROLIDE; ROXITHROMYCIN; SELECTIN; VASCULAR CELL ADHESION MOLECULE 1;

ANTIBODY TITER; ATHEROGENESIS; ATHEROSCLEROSIS; BACTERIAL INFECTION; CARDIOVASCULAR RISK; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; HELICOBACTER PYLORI; HERPES SIMPLEX VIRUS; HUMAN; INFECTION; INFLAMMATION; NONHUMAN; REVIEW; VIRUS INFECTION;

BACTERIA (MICROORGANISMS); CHLAMYDIA; CHLAMYDOPHILA PNEUMONIAE; CYTOMEGALOVIRUS; DNA VIRUSES; HELICOBACTER PYLORI; HERPES; SIMPLEXVIRUS;

EID: 0034068256     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059020-00001     Document Type: Review

References (107)

1. 1. McGovern PG, Pankow JS, Shahar E, et al. Recent trends in acute coronary heart disease mortality, morbidity, medical care, and risk factors. N Engl J Med 1996; 334: 884-90
2. 2. Hunink MG, Goldman L, Tosteson AN, et al. The recent decline in mortality from coronary heart disease, 1980-1990: the effect of secular trends in risk factors and treatment. JAMA 1997; 277: 535-42
3. 3. Jousilahti P, Vartiainen E, Tuomilehto J, et al. Effect of risk factors and changes in risk factors on coronary mortality in three cohorts of middle-aged people in eastern Finland. Am J Epidemiol 1995; 141: 50-60
4. 4. Tervahauta M, Pekkanen J, Enlund H, et al. Change in blood pressure and 5-year risk or coronary heart disease among elderly men: the Finnish cohorts of the Seven Countries Study. J Hypertens 1994; 12: 1183-9
5. 5. Rhoads GG, Dahlen GH, Berg K, et al. LP(a) lipoprotein as a risk factor for myocardial infarction. JAMA 1986; 74: 758-69
6. 6. Janus ED, Postiglione A, Singh RB, et al. The modernization of Asia: implications for coronary heart disease. Circulation 1996; 94: 2671-3
7. 7. Dahlen GH. Lipoprotein (a), atherosclerosis and thrombosis. Prog Lipid Res 1991; 30: 189-97
8. 8. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11
9. 9. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-28
10. 10. Nehler MR, Taylor Jr LM, Porter JM. Homocysteinemia as a risk factor for atherosclerosis: a review. Cardiovasc Surg 1997; 6: 559-67
11. 11. Meyers DG. The iron hypothesis - does iron cause atherosclerosis? Clin Cardiol 1996; 19: 925-9
12. 12. Mehta JL, Saldeen TG, Rand K. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol 1998; 31: 1217-25
13. 13. Alexander RW. Inflammation and coronary artery disease. N Engl J Med 1994; 331: 468-9
14. 14. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-126.
15. 15. Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994; 89: 2462-78
16. 16. Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316: 1371-5
17. 17. Van der Wal AC, Das PK, Bentz van de Berg D, et al. Atherosclerotic lesions in humans: in situ immunophenotypic analysis suggesting an immune-mediated response. Lab Invest 1989; 61: 166-70
18. 18. Raines EW, Rosenfield ME, Ross R. The role of macrophages. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and coronary artery disease. Philadelphia (PA): Lippincott-Raven, 1996: 492-510
19. 19. Libby P, Sukhova G, Lee RT, et al. Cytokines regulate vascular function related to stability of the atherosclerotic plaque. J. Cardiovasc Pharmacol 1995: 12: 2-59
20. 20. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-50
21. 21. Warner SJC, Friedman GB, Libby P. Regulation of major histocompatibility gene expression in cultured human vascular smooth muscle cells. Arteriosclerosis. 1989; 9: 279-88
22. 22. Van der Wal AC, Becker AE, Van der Loos CM, et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89: 36-44
23. 23. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-503
24. 24. Mach F. Schönbeck U, Sukhova GK, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signaling. Nature 1998; 394: 200-3
25. 25. Kostis JB, Turkevich D, Sharp J. Association between leukocyte count and the presence and extent of coronary atherosclerosis as determined by coronary arteriography. Am J Cardiol 1984; 53: 997-9
26. 26. Friedman GD, Klatsky AL, Sieglaub AB. The leukocyte count as a predictor of acute myocardial infarction. N Engl J Med 1974; 290: 1275-8
27. 27. Lowe GD, Machado SG, Krol WF, et al. White blood cell count and hematocrit as predictors of coronary recurrence after myocardial infarction. Thromb Hemost 1985; 54: 700-3.
28. 28. Mehta J, Dinerman J, Mehta P, et al. Neutrophil function in ischemic heart disease. Circulation 1989; 79: 549-56
29. 29. Dinerman JL, Mehta JL, Saldeen TGP, et al. Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarction. J Am Coll Cardiol 1990; 15: 1559-63
30. 30. Neri Serneri GG, Abbate R, Gori et al. Transient intermittent lymphocyte activation is responsible for the instability of angina. Circulation 1992; 86: 790-7
31. 31. Haught WH, Mansour M, Rothlein R, et al. Alterations in circulating intercellular adhesion molecule-1 and L-selectin: further evidence for chronic inflammation in ischemic heart disease. Am Heart J 1996; 132: 1-6
32. 32. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331: 417-24
33. 33. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9
34. 34. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99: 855-60
35. 35. Buja LM. Does atherosclerosis have an infectious etiology? Circulation 1996; 94: 872-3
36. 36. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997; 96: 4095-103
37. 37. Frothingham C. The relation between acute infectious diseases and arterial lesions. Arch Intern Med 1911; 8: 153-62
38. 38. Ophuls W. Arteriosclerosis and cardiovascular disease: their relation to infectious diseases. JAMA 1921; 76: 700-1
39. 39. Fabricant CG, Fabricant J, Litrenta MM, et al. Virus-induced atherosclerosis. J Exp Med 1978; 148: 335-40
40. 40. Mattila KJ. Viral and bacterial infections in patients with acute myocardial infarction. J Intern Med 1989; 225: 293-6
41. 41. Benditt EP, Barrett T, McDougall JK. Viruses in the etiology of atherosclerosis. Proc Natl Acad Sci U S A 1983; 80: 6386-9
42. 42. Zhou YF, Leon MB, Waclawiw MA, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996; 335: 624-30
43. 43. Loebe M, Schuler S, Zais O, et al. Role of cytomegalovirus infection in the development of coronary artery disease in the transplanted heart. J Heart Transplant 1990; 9: 707-11
44. 44. Melnick JL, Adam E, DeBakey ME. Possible role of cytomegalovirus in atherogenesis. JAMA 1990; 263: 2204-7
45. 45. Melnick JL, Adam E, Debakey ME. Cytomegalovirus and atherosclerosis. Eur Heart J 1993; 14: 30-8
46. 46. Kuo CC, Grayston JT, Campbell LA, et al. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natal Acad Sci U S A 1995; 92: 6911-14
47. 47. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; II: 983-6
48. 48. Thom DH, Grayston JT, Siscovick DS, et al. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992; 268: 68-72
49. 49. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 1992; 116: 273-278
50. 50. Folsom AR, Nieto FJ, Sorlie P, et al. Helicobacter pylori seropositivity and coronary heart disease incidence (Atherosclerosis Risk In Communities (ARIC) Study Investigators). Circulation 1998; 98: 845-50
51. 51. Adam E, Melnick JL, Probtsfield JL, et al. High level of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet 1987; II: 291-3
52. 52. Jacob HS, Visser M, Key NS, et al. Herpes virus infection of endothelium: new insights into atherosclerosis. Trans Am Clin Climatol Assoc 1992; 103: 95-104.
53. 53. Span AH, van Dam Mieras MC, et al. The effect of virus infection on the adherence of leukocytes or platelets to endothelial cells. Eur J Clin Invest 1991; 21: 331-8
54. 54. Hendrix MG, Salimans MM, van Boven et al. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol 1990; 136: 23-8
55. 55. Wu TC, Hruban RH, Ambinder RF, et al. Demonstration of cytomegalovirus nucleic acids in the coronary arteries of transplanted hearts. Am J Pathol 1992; 140: 739-47
56. 56. Hendrix MG, Dormans PH, Kitslaar P, et al. The presence of cytomegalovirus nucleic acids in arterial walls of atherosclerotic and non-atherosclerotic patients. Am J Pathol 1998; 134: 1151-7
57. 57. Hendrix MG, Daemen M, Bruggeman CA. Cytomegalovirus nucleic acid distribution within the human vascular tree. Am J Pathol 1991; 138: 563-7
58. 58. Hosenpud JD, Chou SW, Wagner CR. Cytomegalovirus-induced regulation of major histocompatibility complex class I antigen expression in human aortic smooth muscle cells. Transplantation 1991; 52: 896-903
59. 59. Geist LJ, Dai LY. Cytomegalovirus modulates interleukin-6 gene expression. Transplantation 1996; 62: 653-8
60. 60. Galloway DA, McDougall JK. The oncogenic potential of herpes simplex viruses: evidence for a 'hit-and-run' mechanism. Nature 1983; 302: 21-4
61. 61. Nieto FJ, Adam E. Sorlie P, et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 1996; 94: 922-7
62. 62. Heiss G, Sharrett AR, Barnes R, et al. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 1991; 134: 250-6
63. 63. Adler SP, Hur JK, Wang JB, et al. Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J Infect Dis 1998; 177: 209-12
64. 64. Birnie DH, Holme ER, McKay IC, et al. Association between antibodies to heat shock protein 65 and coronary atherosclerosis. Possible mechanism of action of Helicobacter pylori and other bacterial infections in increasing cardiovascular risk. Eur Heart J 1998; 19: 387-94
65. 65. Laurila A, Bloigu A, Nayha S, et al. Association of Helicobacter pylori infection with elevated serum lipids. Atherosclerosis 1999; 142: 207-10
66. 66. Abdelmouttaleb I, Danchin N, Ilardo C, et al. C-Reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes. Am Heart J 1999; 137: 346-51.
67. 67. Danesh J, Peto R. Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies. BMJ 1998; 316: 1130-2
68. 68. Pasceri V, Cammarota G, Patti G, et al. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 1998; 97: 1675-9
69. 69. Fryer RH, Schwobe EP, Woods ML, et al. Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Invest Med 1997; 45: 168-74
70. 70. Gaydos CA, Summersgill JT, Sahney NN, et al. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 1996; 64: 1614-20
71. 71. Wyrick PB, Brunridge EA. Growth of Chlamydia psittaci in macrophages. Infect Immun 1978; 19: 1054-60
72. 72. Godzik KL, O'Brien ER, Wang S, et al. In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J Clin Microbiol 1995; 33: 2411-4
73. 73. Fong IW, Chiu B, Viira E, et al. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 1997; 35: 48-52
74. 74. Moazed TC, Kuo CG, Grayston JT, et al. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Invest Med 1997; 45: 168-74
75. 75. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97: 633-6
76. 76. Hu H, Pierce GN, Zhong G. The atherogenic effects of Chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999: 103: 747-53
77. 77. Romeo F, Ericson K, Saldeen TGP, et al. Seropositivity against Chlamydia pneumoniae in patients with coronary atherosclerosis disease. Clin Cardiol 1999. In press
78. 78. Kuo CC, Coulson AS, Campbell LA, et al. Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction. J Vasc Surg 1997; 26: 29-31
79. 79. Campbell LA, O'Brien ER, Cappuccio AL, et al. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis 1995; 172: 585-8
80. 80. Ouchi K, Fujii B, Kanamoto Y, et al. Chlamydia pneumoniae in coronary and iliac arteries of Japanese patients with atherosclerotic cardiovascular diseases. J Med Microbiol 1998; 47 907-13
81. 81. Juvonen J, Juvonen T, Laurila A, et al. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc Surg 1997; 25: 499-505
82. 82. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 1992; 82: 158-61
83. 83. Muhlestein JB, Hammond EH, Carlquist JF, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996; 27: 1555-61
84. 84. Andreasen JJ, Farholt S, Jensen JS. Failure to detect Chlamydia pneumoniae in calcific and degenerative arteriosclerotic aortic valves excised during open heart surgery. APMIS 1998; 106: 717-20
85. 85. Patherson DL, Hall J, Rasmussen SJ, et al. Failure to detect Chlamydia pneumoniae in atherosclerotic plaques of Australian patients. Pathology 1998; 30: 169-72
86. 86. Weiss SM, Roblin PM, Gaydos CA, et al. Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J Infect Dis 1996; 173: 957-62
87. 87. Saldeen TGP, Ericsson K, Lindquist O, et al. Chlamydia and HLA-DR genotypes in coronary atherosclerosis [abstract]. J Am Coll Cardiol 1998; 31: 272A
88. 88. Dahlen GH, Boman J, Birgander LS, et al. Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis 1995; 114: 165-74
89. 89. Dahlen GH, Slunga L, Lindblom B. Importance of Lp(a) lipoprotein and HLA genotypes in atherosclerosis and diabetes. Clin Genet 1994; 46: 46-56
90. 90. Ossewaarde JM, Ferkens EJ, Devries A, et al. Chlamydia pneumoniae is a risk factor for coronary heart disease in symptomfree elderly men, but Helicobacter pylori and cytomegalovirus are not. Epidemiol Infect 1998; 120: 93-9
91. 91. Blasi F, Denti F, Erba M, et al. Detection of Chlamydia pneumoniae, but not Helicobacter pylori, in atherosclerotic plaques of aortic aneurysms. J Clin Microbiol 1996; 34: 2766-9
92. 92. Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patients with coronary atherosclerosis, the Chlamydia pneumoniae/atherosclerosis study group. Ann Intern Med 1996; 125: 979-82
93. 93. Jackson LA, Campbell LA, Schmidt RA, et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol 1997; 150: 1785-90
94. 94. Danesh J, Wong Y, Ward M, et al. Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: population based study of coronary heart disease. Heart 1999; 81: 245-7
95. 95. Danesh J, Wong YK, Ward M, et al. Strong correlation between Helicobacter pylori seropositivity and Chlamydia pneumoniae IgG concentrations. J Epidemiol Community Health 1998; 52: 821-2
96. 96. Kol A, Sukhova GK, Lichtman AH, et al. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998; 98: 300-7
97. 97. Mayr M, Metzler B, Kiechl S, et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae. Circulation 1999; 99: 1560-6
98. 98. Kalayoglu MV, Byrne GI. A Chlamydia pneumoniae component that induces macrophage foam cell formation is Chlamydial lipopolysaccharide. Infect Immun 1998; 66: 5067-72
99. 99. Rasmussen SJ, Eckmann L, Quayle AJ, et al. Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in Chlamydial pathogenesis. J Clin Invest 1997; 99: 77-87
100. 100. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990; 70: 427-51
101. 101. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-42
102. 102. Carbon C. Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogens. Clin Infect Dis 1998; 27: 28-32
103. 103. Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithronmycin in male survivors of acute myocardial infarction. Circulation 1997; 96: 404-7
104. 104. Gurfinkel E, Bozovich G, Daroca A, et al., ROXIS Study Group. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997; 350: 404-7
105. 103. Gurfinkel E, Bozovich G, Beck E, et al. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: the final report of the ROXIS study. Eur Heart J 1999; 20: 121-7
106. 106. Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. Circulation 1999; 99: 1540-7
107. 107. Martin D, Bursill J, Qui MR, et al. Alternative hypothesis for efficacy of macrolides in acute coronary syndromes. Lancet 1998; 351: 1858-9